Tuesday, September 13, 2016 8:49:45 PM
Volume Weighted Average Price
$0.704 ... Sep 13, 2016
$0.715 ... Sep 12, 2016
$0.745 ... Sep 09, 2016
$0.687 ... Sep 08, 2016
$0.647 ... Sep 07, 2016
$0.624 ... Sep 06, 2016
$0.626 ... Sep 02, 2016
$0.617 ... Sep 01, 2016
$0.607 ... Aug 31, 2016
$0.604 ... Aug 30, 2016
$0.622 ... Aug 29, 2016
$0.618 ... Aug 26, 2016
$0.584 ... Aug 25, 2016 << Lowest Avg Price in 8 months
$0.586 ... Aug 24, 2016
$0.591 ... Aug 23, 2016
$0.590 ... Aug 22, 2016
$0.596 ... Aug 19, 2016
$0.621 ... Aug 18, 2016
$0.622 ... Aug 17, 2016
$0.597 ... Aug 16, 2016
$0.616 ... Aug 15, 2016
$0.654 ... Aug 12, 2016
$0.627 ... Aug 11, 2016
$0.607 ... Aug 10, 2016
$0.598 ... Aug 09, 2016
$0.611 ... Aug 08, 2016
$0.622 ... Aug 05, 2016
$0.616 ... Aug 04, 2016
$0.614 ... Aug 03, 2016
$0.610 ... Aug 02, 2016
$0.616 ... Aug 01, 2016
$0.616 ... Jul 29, 2016
$0.615 ... Jul 28, 2016
$0.618 ... Jul 27, 2016
$0.615 ... Jul 26, 2016
$0.623 ... Jul 25, 2016
$0.637 ... Jul 22, 2016
$0.654 ... Jul 21, 2016
$0.656 ... Jul 20, 2016
$0.637 ... Jul 19, 2016
$0.615 ... Jul 18, 2016
$0.620 ... Jul 15, 2016
$0.625 ... Jul 14, 2016
$0.622 ... Jul 13, 2016
$0.626 ... Jul 12, 2016
$0.632 ... Jul 11, 2016
$0.635 ... Jul 08, 2016
$0.652 ... Jul 07, 2016
$0.640 ... Jul 06, 2016
$0.624 ... Jul 05, 2016
$0.631 ... Jul 01, 2016
$0.640 ... Jun 30, 2016
$0.637 ... Jun 29, 2016
$0.661 ... Jun 28, 2016
$0.628 ... Jun 27, 2016
$0.666 ... Jun 24, 2016
$0.706 ... Jun 23, 2016
$0.709 ... Jun 22, 2016
$0.708 ... Jun 21, 2016
$0.707 ... Jun 20, 2016
$0.744 ... Jun 17, 2016
$0.734 ... Jun 16, 2016
$0.728 ... Jun 15, 2016
$0.734 ... Jun 14, 2016
$0.759 ... Jun 13, 2016
$0.788 ... Jun 10, 2016
$0.768 ... Jun 09, 2016
$0.771 ... Jun 08, 2016
$0.795 ... Jun 07, 2016
Recent SNGX News
- Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa • PR Newswire (US) • 04/25/2024 11:30:00 AM
- Soligenix Announces Pricing of $4.75 Million Public Offering • PR Newswire (US) • 04/18/2024 12:30:00 PM
- FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection • PR Newswire (US) • 04/15/2024 11:30:00 AM
- FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection • PR Newswire (US) • 04/11/2024 11:30:00 AM
- Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency • PR Newswire (US) • 04/03/2024 11:30:00 AM
- Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results • PR Newswire (US) • 03/15/2024 11:30:00 AM
- Soligenix Announces Formation of Behçet's Disease Medical Advisory Board • PR Newswire (US) • 02/08/2024 12:30:00 PM
- Soligenix to Present at The Microcap Conference • PR Newswire (US) • 01/25/2024 12:30:00 PM
- FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease • PR Newswire (US) • 01/08/2024 12:30:00 PM
- Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis • PR Newswire (US) • 01/04/2024 12:30:00 PM
- Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses • PR Newswire (US) • 01/02/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 09:05:29 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/18/2023 05:15:36 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:10:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:10:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:10:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:10:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/15/2023 09:03:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 10:12:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 10:11:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 10:10:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 10:10:16 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 12/08/2023 09:05:59 PM
- "HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug Discovery • PR Newswire (US) • 12/01/2023 12:30:00 PM
- Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease • PR Newswire (US) • 11/30/2023 12:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM